Mankind Pharma Q4 Results Review - Strong Performance From Formulation; Consumer Health Subdued: Dolat Capital

Dolat Capital Report

Mankind Pharma Ltd.'s Q4 FY24 results came above our estimates due to-

1. better than expected gross margin,

2. lower other expense and

3. higher other income.

However sales came in-line with estimates.

For FY25 management guided mid-teens revenue growth for its export (ex one-off) and consumer business, along with overall Ebitda margin of 25- 26%. The company will look at combination of debt and equity raise for any acquisition and will maintain financial discipline.

Balance sheet not likely to become overleveraged and debt/Ebitda will not exceed 2-2.5 times. Management also guided that it will not go ahead with any acquisition that is Ebitda margin or return on capital employed dilutive.

We upgrade our FY25E/FY26E EPS estimates by 1.5%/1.4% assuming higher other income. Maintain ‘Accumulate’ rating with revised target price of Rs 2,554 (earlier Rs 2,520) at 38 times (adjusted for amortisation) FY26E price/earning.

Key risks: Adverse pricing regulation in India by NPPA and compliance issues on any facilities.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.